(Q35915916)

11 August 2017

1 reference

title

Pharmacologic perspectives for once-daily antiretroviral therapy (English)

1 reference

11 August 2017

anti-retroviral agent

0 references

author name string

Peter L Anderson

series ordinal

1

1 reference

PubMed ID

15479772

11 August 2017

language of work or name

English

0 references

publication date

12 October 2004

1 reference

Annals of Pharmacotherapy

11 August 2017

1 reference

11 August 2017

38

1 reference

11 August 2017

11

1 reference

11 August 2017

1924-1934

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

11 August 2017

1 reference

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens

21 January 2018

1 reference

Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life.

21 January 2018

1 reference

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection

21 January 2018

1 reference

Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients

21 January 2018

1 reference

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

21 January 2018

1 reference

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

21 January 2018

1 reference

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

21 January 2018

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

21 January 2018

1 reference

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities

21 January 2018

1 reference

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

21 January 2018

1 reference

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors

21 January 2018

1 reference

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects

21 January 2018

1 reference

A prospective study of predictors of adherence to combination antiretroviral medication

21 January 2018

1 reference

Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units

21 January 2018

1 reference

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

21 January 2018

1 reference

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

21 January 2018

1 reference

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

Selective versus universal antenatal HIV testing: epidemiological and implementational factors in policy choice.

21 January 2018

1 reference

Therapeutic drug monitoring in HIV infection: current status and future directions

21 January 2018

1 reference

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

21 January 2018

1 reference

Atazanavir: a novel HIV-1 protease inhibitor

21 January 2018

1 reference

Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients

21 January 2018

1 reference

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

21 January 2018

1 reference

21 January 2018

1 reference

Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells

21 January 2018

1 reference

Tenofovir disoproxil fumarate

21 January 2018

1 reference

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

21 January 2018

1 reference

Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients

21 January 2018

1 reference

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

21 January 2018

1 reference

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study

21 January 2018

1 reference

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study

21 January 2018

1 reference

P glycoprotein in human immunodeficiency virus type 1 infection and therapy

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

21 January 2018

1 reference

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

21 January 2018

1 reference

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

The abacavir hypersensitivity reaction: a review

21 January 2018

1 reference

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type

21 January 2018

1 reference

Resistance, fitness, adherence, and potency: mapping the paths to virologic failure.

21 January 2018

1 reference

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

21 January 2018

1 reference

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E036

1 reference

11 August 2017

1 reference

PubMed ID

15479772